SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
450.00    -3.60 (-0.79%)
Bid:
451.30
Ask:
451.60
Spread: 0.30 (0.066%)
Market Cap: £11.32b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

3rd Quarter Trading Update

17 Oct 2019 07:00

RNS Number : 1461Q
Rentokil Initial PLC
17 October 2019
Β 

Β Β 

17 October 2019

RENTOKIL INITIAL PLC - THIRD QUARTER TRADING UPDATE

Β 

Another strong quarter: Ongoing Organic Revenue growth of 5.5% our highest level in over 10 years, continued progress in M&A, on track to meet expectations for the full year

Β 

Β 

(Β£m)

Q3 2019

Growth

AER

AER

CER

Ongoing Revenue1

723.0

13.6%

9.8%

Revenue

727.2

13.4%

9.6%

Β 

Overview (CER)

Β 

Ongoing Revenue increased by 9.8% in Q3, of which 5.5% was Organic2 (H1 2019: 4.2%, Q3 2018: 4.1%) and 4.3% was from acquisitions.

Ongoing revenue in Pest Control grew by 12.3% (5.9% Organic), with good performances delivered across both Growth and Emerging markets, which grew by 12.2% and 12.7% respectively. Our North American, UK & Rest of World and Latin American operations delivered particularly good growth in the period.

Our Hygiene business performed well during the quarter, with Ongoing Revenue increasing by 5.5%, and Organic Revenue rising by 4.8%. This reflects good growth in the UK, Europe and Pacific and the ongoing contribution from acquisitions.

Ongoing Revenue in our Protect & Enhance category grew by 4.9% (4.5% Organic), reflecting a solid performance from both France Workwear and Ambius, and an improved performance from our UK Property Care business which encouragingly delivered positive growth.

During the third quarter the Company undertook its biennial survey of our 40,000 colleagues around the world. 90% of our colleagues participated and the results continued to place Rentokil Initial in the global High Performance group of leading companies for both Colleague Engagement and Enablement.

M&A

​We acquired 15 businesses in the quarter across all of our regions (except Pacific), with annualised revenues of c. Β£15m. 12 Pest Control businesses were acquired, predominantly in North America and Latin America. For the year to 30 September 2019 we have acquired a total of 32 businesses (24 in Pest Control, five in Hygiene and three in Protect & Enhance) primarily in Emerging and Growth markets. Annualised revenues of the businesses acquired so far in 2019 totalled c. Β£70m in the year prior to purchase. Our M&A pipeline going into Q4 and 2020 remains strong.

Conclusion of CMA reviews

Β 

The CMA's reviews into the acquisitions of Cannon UK and MPCL (formerly Mitie Pest) concluded on 30 September following completion of the partial divestments required on each by the CMA. Integration of the retained businesses is now proceeding at pace.

​Commenting on today's announcement Andy Ransom, Chief Executive, said:

"I am pleased with our Q3 results and our Group Organic Growth of 5.5% is our highest level of quarterly Organic Growth in over a decade. Pest Control has performed well, growing organically by 5.9%, and Hygiene has demonstrated further momentum, growing organically by 4.8%. Our performance in Q3, combined with further progress in our value-creating M&A programme, means we remain on track to meet expectations for the full year.

"I am also delighted to see the excellent results of our colleague survey. We continue to deliver world-class standards of colleague engagement and enablement, and we see this in turn resulting in outstanding service for our customers and higher levels of retention. I'd like to thank all of our colleagues for their ongoing commitment and determination to be the best at what we do."

Β 

Β 

Enquiries:

Β 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

Media:

Malcolm Padley

Rentokil Initial plc

07788 978 199

Β 

Β 

1Ongoing Revenue represents the performance of the continuing operations of the Group (including acquisitions) after removing the effect of disposed or closed businesses.

Β 

2Organic Revenue represents the growth in Ongoing Revenue excluding the effect of businesses acquired during the year. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations.

Β 

AER - actual exchange rates; CER - constant 2018 exchange rates

Β 

This announcement contains statements that are, or may be, forward-looking regarding the Group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure Guidance and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
TSTBLBDGUUBBGCL
Date   Source Headline
28th Jul 20253:00 pmRNSHolding(s) in Company
10th Jul 202511:00 amRNSHolding(s) in Company
1st Jul 202510:25 amRNSTotal Voting Rights
10th Jun 202510:05 amRNSAdditional Listing
3rd Jun 20254:00 pmRNSDirector/PDMR Shareholding
28th May 20257:00 amRNSSale of France Workwear
19th May 20252:30 pmRNSDirector/PDMR Shareholding
7th May 20254:15 pmRNSResult of AGM
7th May 20257:01 amRNSDirectorate Change: Appointment of NEDs
7th May 20257:00 amRNSDirectorate Change: Chief Executive to retire
28th Apr 20252:30 pmRNSIssue of Debt
17th Apr 20252:20 pmRNSHolding(s) in Company
17th Apr 20257:00 amRNSQ1 Trading Update
9th Apr 202510:25 amRNSHolding(s) in Company
1st Apr 20252:15 pmRNSNotice of Q1 Trading Update and Management Call
1st Apr 202510:25 amRNSBlock listing Interim Review
27th Mar 202510:25 amRNSDirector/PDMR Shareholding
26th Mar 202510:30 amRNSAnnual Financial Report
14th Mar 202510:00 amRNSDirector/PDMR Shareholding
6th Mar 20257:00 amRNSFinal Results
28th Jan 20257:00 amRNSTrading Update (unaudited)
14th Jan 202511:15 amRNSHolding(s) in Company
13th Jan 202511:15 amRNSHolding(s) in Company
13th Dec 20249:30 amRNSDirector/PDMR Shareholding
25th Nov 20247:00 amRNSDirectorate Change
12th Nov 202410:30 amRNSHolding(s) in Company
8th Nov 202410:30 amRNSHolding(s) in Company
17th Oct 20247:00 amRNSQ3 Trading Update
1st Oct 20242:00 pmRNSBlock listing Interim Review
25th Sep 20247:00 amRNSAppointment of Non-Executive Director
19th Sep 202410:30 amRNSDirector/PDMR Shareholding
11th Sep 20247:00 amRNSTrading Update
10th Sep 202410:30 amRNSHolding(s) in Company
5th Sep 202411:08 amRNSHolding(s) in Company
25th Jul 20247:00 amRNS2024 Interim Results
10th Jul 20244:35 pmRNSHolding(s) in Company
26th Jun 20245:12 pmRNSDirector/PDMR Shareholding
26th Jun 202411:08 amRNSHolding(s) in Company
17th May 20243:30 pmRNSDirector/PDMR Shareholding
8th May 20242:00 pmRNSResult of AGM
29th Apr 20243:00 pmRNSHolding(s) in Company
23rd Apr 20249:30 amRNSHolding(s) in Company
18th Apr 20247:00 amRNSQ1 Trading Update
2nd Apr 20241:28 pmRNSBlock listing Interim Review
2nd Apr 202412:17 pmRNSTotal Voting Rights
27th Mar 202410:23 amRNSAnnual Financial Report
19th Mar 20242:05 pmRNSAdditional Listing
14th Mar 202410:19 amRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSFinal Results
1st Dec 20237:00 amRNSNorth American Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.